This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAMBURG, Germany, March 21, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) is going to broadcast its press & analyst conference in Frankfurt live on the internet. The Management Board of Evotec AG will inform you about the FY 2010 results as well as the status of the Discovery Alliance Business and the Company's development projects. Moreover, they will provide an update on the "Evotec 2012 – Action Plan to Focus and Grow" and the business outlook for 2011. The conference will be held in English.
Thursday, 24 March 2011
10.00 am CET (09.00 am GMT/05.00 am EDT)
To join the
audio webcast and to access the
presentation slides you will find a link on our home page
www.evotec.com shortly before the event.
For those who prefer to listen to the presentation via
phone, please dial:
+49 (0)69 20 17 44 210
+44 207 153 9154
+1 877 423 0830
The on-demand version of the webcast will be available on our website:
www.evotec.com - Investors – Events - Financial Calendar.
ABOUT EVOTEC AG
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology, inflammation and metabolic diseases. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, MedImmune, CHDI, Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression and an alliance in the field of diabetes with Andromeda (Teva). For additional information please go to
CONTACT: Dr. Werner Lanthaler
Chief Executive Officer
+49.(0)40.560 81-333 Fax
22525 Hamburg (Germany)